Chembio Diagnostics ROE 2006-2018 | CEMI

Current and historical return on equity (ROE) values for Chembio Diagnostics (CEMI) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Chembio Diagnostics ROE for the three months ending December 31, 2018 was -31.85%.
Chembio Diagnostics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-12-31 $-0.01B $0.03B -32.32%
2018-09-30 $-0.01B $0.02B -35.44%
2018-06-30 $-0.01B $0.02B -32.43%
2018-03-31 $-0.01B $0.02B -35.82%
2017-12-31 $-0.01B $0.01B -46.67%
2017-09-30 $-0.01B $0.02B -50.00%
2017-06-30 $-0.01B $0.02B -52.17%
2017-03-31 $-0.02B $0.02B -95.24%
2016-12-31 $-0.01B $0.02B -82.54%
2016-09-30 $-0.01B $0.02B -68.75%
2016-06-30 $-0.01B $0.01B -58.06%
2016-03-31 $-0.00B $0.02B -11.11%
2015-12-31 $-0.00B $0.02B -16.22%
2015-09-30 $-0.00B $0.02B -10.53%
2015-06-30 $-0.00B $0.02B -10.26%
2015-03-31 $-0.00B $0.02B -5.06%
2014-12-31 $0.00B $0.02B 0.00%
2014-09-30 $0.00B $0.02B 0.00%
2014-06-30 $0.00B $0.02B 5.00%
2014-03-31 $0.00B $0.02B 5.00%
2013-12-31 $0.00B $0.02B 5.41%
2013-09-30 $0.00B $0.02B 5.88%
2013-06-30 $0.00B $0.02B 0.00%
2013-03-31 $0.00B $0.01B 0.00%
2012-12-31 $0.00B $0.01B 0.00%
2012-09-30 $0.01B $0.01B 46.15%
2012-06-30 $0.01B $0.01B 52.17%
2012-03-31 $0.01B $0.01B 63.16%
2011-12-31 $0.01B $0.01B 77.42%
2011-09-30 $0.00B $0.01B 32.00%
2011-06-30 $0.00B $0.01B 36.36%
2011-03-31 $0.00B $0.01B 60.00%
2010-12-31 $0.00B $0.01B 70.59%
2010-09-30 $0.00B $0.00B 28.57%
2010-06-30 $0.00B $0.00B 30.77%
2010-03-31 $0.00B $0.00B 0.00%
2009-12-31 $0.00B $0.00B 0.00%
2009-09-30 $-0.00B $0.00B -40.00%
2009-06-30 $-0.00B $0.00B -40.00%
2009-03-31 $-0.00B $0.00B -36.36%
2008-12-31 $-0.00B $0.00B -61.54%
2008-09-30 $-0.01B $0.00B -171.43%
2008-06-30 $-0.01B $0.00B -186.67%
2008-03-31 $-0.01B $0.00B -188.24%
2007-12-31 $-0.01B $0.00B -177.78%
2007-09-30 $-0.01B $0.00B -120.00%
2007-06-30 $-0.01B $0.01B -155.56%
2007-03-31 $-0.01B $0.01B -215.38%
2006-12-31 $-0.01B $0.01B -355.56%
2006-09-30 $-0.01B $0.00B -600.00%
2006-06-30 $-0.01B $0.00B -500.00%
2006-03-31 $-0.01B $0.00B -285.71%
2005-12-31 $-0.01B $0.00B -280.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.099B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.412B 27.76
Medtronic (MDT) Ireland $123.010B 17.98
Stryker (SYK) United States $73.467B 26.97
Boston Scientific (BSX) United States $52.473B 25.58
Baxter (BAX) United States $39.558B 25.31
Zimmer Biomet Holdings (ZBH) United States $26.051B 16.68
Smith & Nephew SNATS (SNN) United Kingdom $17.542B 0.00
Canopy Growth (CGC) Canada $15.685B 0.00
ResMed (RMD) United States $14.159B 26.85
Aurora Cannabis (ACB) Canada $9.930B 70.07
Bio-Rad Laboratories (BIO) United States $9.309B 53.12
Hill-Rom Holdings (HRC) United States $6.934B 21.44
Perrigo (PRGO) Ireland $6.569B 10.65
Insulet (PODD) United States $5.896B 1989.40
GW Pharmaceuticals (GWPH) United Kingdom $5.140B 0.00
ICU Medical (ICUI) United States $4.857B 30.24
Haemonetics (HAE) United States $4.425B 39.25
Hutchison China MediTech (HCM) China $3.913B 0.00
Agios Pharmaceuticals (AGIO) United States $3.752B 0.00
Neogen (NEOG) United States $3.328B 51.11
NuVasive (NUVA) United States $2.858B 24.93
Quidel (QDEL) United States $2.654B 23.95
Aphria (APHA) $2.533B 112.44
National Vision Holdings (EYE) United States $2.263B 44.51
HEXO (HEXO) $1.414B 0.00
Cardiovascular Systems (CSII) United States $1.377B 988.50
VAREX IMAGING (VREX) United States $1.295B 25.34
Phibro Animal Health (PAHC) United States $1.292B 18.57
AtriCure (ATRC) United States $1.089B 0.00
MacroGenics (MGNX) United States $0.939B 0.00
Lantheus Holdings (LNTH) United States $0.930B 25.13
Cerus (CERS) United States $0.874B 0.00
Omeros (OMER) United States $0.861B 0.00
PetIQ (PETQ) United States $0.843B 24.12
NanoString Technologies (NSTG) United States $0.751B 0.00
Meridian Bioscience (VIVO) United States $0.722B 21.52
OraSure Technologies (OSUR) United States $0.705B 30.89
Evolus (EOLS) United States $0.685B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.667B 22.70
TG Therapeutics (TGTX) United States $0.655B 0.00
LeMaitre Vascular (LMAT) United States $0.609B 28.99
Surmodics (SRDX) United States $0.603B 87.71
Quanterix (QTRX) United States $0.545B 0.00
BioLife Solutions (BLFS) United States $0.376B 154.92
Rockwell Medical (RMTI) United States $0.367B 0.00
Insys Therapeutics (INSY) United States $0.352B 0.00
Vapotherm (VAPO) United States $0.330B 0.00
Utah Medical Products (UTMD) United States $0.315B 20.48
Owens & Minor (OMI) United States $0.284B 3.94
Bovie Medical (APYX) United States $0.266B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.265B 0.00
Cytosorbents (CTSO) United States $0.260B 0.00
Zynex (ZYXI) United States $0.144B 15.37
Fonar (FONR) United States $0.142B 7.59
Surface Oncology (SURF) United States $0.126B 0.00
Chimerix (CMRX) United States $0.102B 0.00
Female Health (VERU) United States $0.095B 0.00
United-Guardian (UG) United States $0.088B 18.43
Conatus Pharmaceuticals (CNAT) United States $0.087B 0.00
InfuSystems Holdings (INFU) United States $0.086B 0.00
CAS Medical Systems (CASM) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.070B 20.71
Oramed Pharmaceuticals (ORMP) United States $0.057B 0.00
Neurotrope (NTRP) United States $0.055B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Valeritas Holdings (VLRX) United States $0.037B 0.00
Senestech (SNES) United States $0.027B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.016B 0.00
Akers Biosciences Inc (AKER) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
NeuroMetrix (NURO) United States $0.009B 16.00